Seith Douglas J
Known title: Chief Operating OfficerCIK: 0001565823
Associated companies
Transaction History
| ATRC | ▲ Buy | Grant | 527 | $13K | 6/30/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 25,532 | $0 | 3/1/2026 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 22,948 | $717K | 3/1/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 42,386 | $0 | 3/1/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 257 | $7K | 12/31/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 550 | $14K | 6/30/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 32,266 | $0 | 3/1/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 12,120 | $0 | 3/1/2025 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 15,050 | $583K | 3/1/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 707 | $14K | 6/28/2024 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 14,596 | $530K | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 37,899 | $0 | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 19,205 | $0 | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 557 | $21K | 6/30/2023 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 11,687 | $454K | 3/1/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 15,453 | $0 | 3/1/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 27,054 | $0 | 3/1/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 609 | $21K | 12/30/2022 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 11,440 | $796K | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 12,573 | $0 | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 13,182 | $0 | 3/1/2022 | View on chart |
| ATRC | ▼ Sell | Open Market | 21,444 | $1.6M | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BTIG raises AtriCure price target to $63
BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.
BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.